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Alzheimer’s disease (AD) is a complex disease resulting in neurodegeneration and cognitive impairment. Investigations
on environmental factors implicated in AD are scarce and the etiology of the disease remains up to now obscure. The
disease’s pathogenesis may be multi-factorial and different etiological factors may converge during aging and induce
an activation of brain microglia and macrophages. This microglia priming will result in chronic neuro-inflammation
under chronic antigen activation. Infective agents may prime and drive iper-activation of microglia and be partially
responsible of the induction of brain inflammation and decline of cognitive performances. Age-associated immune
dis-functions induced by chronic sub-clinical infections appear to substantially contribute to the appearance of
neuro-inflammation in the elderly. Individual predisposition to less efficient immune responses is another relevant
factor contributing to impaired regulation of inflammatory responses and accelerated cognitive decline.
Life-long virus infection may play a pivotal role in activating peripheral and central inflammatory responses and in turn
contributing to increased cognitive impairment in preclinical and clinical AD.
Keywords: Alzheimer’s disease, Herpes virus latency, Peripheral inflammation, Neuro-inflammation, Inflammatory
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Alzheimer dementia type and infections
Alzheimer’s disease (AD) is a progressive neurodegener-
ative disorder and the most common cause of dementia.
According to the World Health Organization, nearly
35.6 millions of people worldwide currently may suffer
from dementia. The disease affects people in all coun-
tries with more than half patients living in low- and
middle-income countries and by 2050, this figure is
likely to rise to more than 70% [1].
Because of the urgency for effective preventive and
therapeutic measures, extensive research has focused on
pathogenetic mechanisms of AD, however, up to now,
no therapy has been found.
Some neuro-pathological alterations such as amyloid
deposition and neurofibrillary tangles (NFTs) are almost* Correspondence: federico.licastro@unibo.it
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unless otherwise stated.always found in the brain after the autopsy examination
of patients who suffered dementia. Therefore, these
alterations have been suggested to be causative of the
disease [2,3]. However, these pathological alterations are
also present in the brain of elderly who died without the
clinical presentation of AD [4] and the notion that
amyloid deposition and other proteinaceous alterations
might be causative of AD is made uncertain by these
observations.
Amyloid beta peptide (Abeta) is the major component
of amyloid deposits in AD brains [2] and derives from
the processing of a highly conserved membrane protein
named amyloid precursor protein (APP) [5]. The physio-
logical function of APP and its biological role remain
unclear [6]. However, few years ago a role as anti-
microbial defensive factor for A-beta peptide has been
suggested [7]. A recent investigation confirmed that the
A-beta peptides showed a relevant anti-virus activity
in vitro and suggested that these peptides may have a
defensive role against the influenza virus [8].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Herpes family and dementia
In our previous publications [9,10] we discussed genetic
data from four genome wide association (GWA) studies
on AD [11-14]. From these investigations a set of single-
nucleotide polymorphisms (SNPs) associated with AD
emerged and we suggested that the concomitant pres-
ence of these SNPs might result in a genetic signature
predisposing to AD, via complex and diverse mecha-
nisms, each contributing to an increase of individual
susceptibility to herpes virus infection [9,10].
A viral etiology, especially involving herpes virus in
AD, has been already proposed and most investigations
have shown an association of herpes simplex virus type
1 (HSV-1) with AD [15-19].
HSV-1 is a ubiquitous virus that affects more than
80% of people over 65 worldwide. It is a neurotropic
double-stranded DNA virus that primarily infects epithe-
lial cells of oral and nasal mucosa. Here virus undergoes
lytic replication; the newly produced viral particles may
enter sensory neurons and, by axonal transport, reach
the trigeminal ganglion where usually establishes a latent
infection. The virus undergoes periodic reactivation cy-
cles in which the newly formed viral particles are trans-
ported back to the site of primary infection through the
sensory neurons, causing the well-known clinical lesions
(i.e., cold sores and blisters). However, the bipolar tri-
geminal ganglion neurons also project to the trigeminal
nuclei located in the brainstem. From here, neurons pro-
ject to the thalamus to finally reach the sensory cortex.
This is the path through which the reactivated virus may
reach the central nervous system (CNS), where it may
cause acute neurological disorders like encephalitis [her-
pes simplex encephalitis (HSE)] or a mild, clinically
asymptomatic, infection, or establish life-long latent in-
fection [20].
Recent reports showed a significant association of
HSV-1 infection with AD risk in a longitudinal nested
study from Sweden [21]. A reactivation of HSV-1 infection
assessed by increased serum levels of specific anti-HSV-1
antibodies was found associated with an increased AD risk
in a longitudinal study on 3432 elderly [21]. Another study
from Italy reported that elevated serum HSV-1 antibody
titers correlated with cortical grey matter volume as
assessed by MRI [22].
It is interesting to note that others herpes viruses
share the ability to become latent in the infected host
and eventually latently infect neurons.
On the other hand, investigations focused on different
viruses of the herpes family, such as human cytomegalo-
virus (CMV), Epstein-Barr virus (EBV) or human herpes
virus 6 (HHV-6) in AD are limited.
CMV is ubiquitously distributed in human popula-
tion and the most frequent brain infection in immunecompromised patients or in infants with congenital
virus transmission [23]. Postnatal acute peripheral
CMV infection is usually asymptomatic, but once
established, the virus remains latent in blood mono-
cytes [24].
CMV has also been associated with other chronic
diseases of aging, including cardiovascular disease, cog-
nitive decline and cancer. The specific mechanisms re-
sponsible for these associations have not been fully
understood, but they are likely to have an immune and
inflammatory component [25].
The sero-conversion to positive CMV may vary over
the years, ranging between 0.5 to 1.5% per year. It has
been suggested that CMV is responsible for the age-
associated immune changes in the elderly which lead to
a reduction in the number of naïve T cells [26,27].
An increased rate of cognitive decline over a four year
period in subjects with elevated CMV antibody levels
has also been reported [28]. Previous work upon brain
frontal and temporal cortex samples found that both AD
patients and elderly healthy subjects were positive for
CMV with no statistically significant difference between
the two groups [29]. CMV was found in the brain of a
greater proportion of patients with vascular dementia
than normal elderly; these findings suggested a role for
this virus in the disease [30].
Our recent work showed that increased CMV antibody
levels were present in the elderly who developed clinical
AD during a five years follow up [31].
Findings from another investigation reported that CMV
infection doubled the risk of developing AD in a longitu-
dinal follow up of 849 participants from USA [32].
EBV infects more than 95% of human beings within
the first years of life. The virus causes acute infectious
mononucleosis in a minority of immune competent
subjects, while the majority develops a lifelong asymp-
tomatic infection and the virus remains latent in B-
lymphocytes. EBV is also involved in the development of
several diseases such as Burkitt lymphoma, Hodgkin
lymphoma and nasopharyngeal carcinoma [33].
Moreover, EBV seems to be involved in the pathogenesis
of various neurological diseases, such as encephalitis,
neuritis, myelitis, cerebellitis, acute disseminated enceph-
alomyelitis, or central nervous system (CNS) lymphoma in
patients with the immunodeficiency virus (HIV) infection
[34] and multiple sclerosis [35].
Recently our findings showed an association of periph-
eral blood positivity for EBV genome and AD [31].
Moreover, elevated levels of EBV specific antibodies were
associated with an increased AD risk [31].
HHV-6 is a neurotropic virus and has been associated
with multiple neurological diseases including seizures,
encephalitis, mesial temporal lobe epilepsy and multiple
sclerosis [36].
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brains than age-matched control (CTR) brains [29].
However, these findings were not confirmed by another
investigation [37] that reported a higher value of HHV-6
level in CTR brains.
Our findings showed an elevated positivity in brains
and peripheral blood for HHV-6 genome in AD [31]. In-
creased sero-positivity was also associated with clinical
diagnosis of AD [31].
The sero-positivity to CMV, EBV or HHV-6 is very
high worldwide and viruses of the herpes family are
largely and commonly present in the elderly.
It is of interest to note that the immune response of
the host to infections undergoes age-dependent changes
following a process called immune senescence. Immune
senescence may lead to an increased susceptibility of
older adults to develop, not only infectious disease, but
also Alzheimer’s disease, osteoporosis, cancer and auto-
immunity [38].The impact of persistent virus infections upon the
impairment of immune responses in the elderly
The aging of the immune system is a continuous and
dynamic process and it might be secondary to mecha-
nisms activated by the response to the pathogen individ-
ual internal milieu [39].
No all immune responses show the same rate of aging
or senescence. In fact, innate immunity seems to be pre-
served along the years, while adaptive immune responses
progressively decline with age [40].
Recent investigations focused on immune senescence
suggested that the progressive decline of immune defense
efficiency might be an adaptation mechanism to the
microorganism exposure experienced by the aging organ-
ism over the life time [41].
A pivotal question, therefore, is: what is the cause of
the progressive senescence of the adaptive immune re-
sponses in the elderly?
Longitudinal investigations showed that T cell pheno-
types and functions progressively change with advancing
age and these populations in the peripheral blood of the
elderly consist of super specialized CD4 positive and CD8
positive T lymphocyte populations [42,43]. These T cell
populations appeared to be immunologically exhausted
according to some Authors [43].
It is interesting to note that the common presence of
CMV sero-positivity in the elderly is associated to an age
related increase of specialized CD8T cells specific for
CMV antigens [44]. Moreover, other chronic virus infec-
tions also contribute to shape the immune phenotype
during aging and their collective immune pressure
changes the representation of peripheral T cell popula-
tions in the elderly [41].Naïve T cells are positive for the following surface
markers: CCR7, CD45RA, CD27 and CD28. Central
memory T cells (CM) are positive for CCR7, CD27 and
CD28 markers. Memory T effector cells (EM) are lightly
positive for CD27 and CD28. Finally, the terminal differ-
entiated memory T cells (TEMRA) are positive for
CD45RA and KLRG-1 surface markers [41].
A summary of the immune impact of virus infection
on human circulating T cells representation is reported
in Table 1 [41].
EBV, varicella zoster virus and HSV-1 have a severe
impact on immune system and contribute to reshape the
immune phenotype in the old person by inducing a per-
sistent antigenic stimulation [45].
For instance, viruses of the herpes family infect the
majority of human population since childhood and by
frequent cycle of reactivation and latency constantly
challenge the immune response and drive the accumula-
tion of memory T cells. Therefore, the continuous antigen
stimulation induced by chronic infectious microorganisms
activates a peripheral chronic inflammatory response that
progressively induces the loss of naïve and inducible CD4
and CD8 positive T cells and the accumulation of memory
T cell populations.
The change in the percentage and the absolute num-
ber of regulatory T cells (Tregs) plays a peculiar rele-
vance in the age dependent re-shaping in the human
immune phenotype. In fact, a progressive loss of indu-
cible Tregs and an increment of naturally occurring
Tregs characterized T cell population change in the eld-
erly, as shown in Figure 1 [41].
We can conclude that during aging a constant antigen
pressure is partially responsible for the age associated
immune decline.
In fact, with advancing age the adaptive immune re-
sponse, the immune diversity and the plasticity of im-
mune responses decline because of the immune reserve
decrease induced by antigen load of chronic infections.
This process is represented in Figure 2 [41].
Chronic infections represent important environmental
factors able to induce a re-shaping of the immune sys-
tem by antigen load during aging. Chronic sub-clinical
viral infections such as those caused by herpes viruses
with their characteristic cycles of latency and reactiva-
tion may play a relevant role. These viruses indeed infect
a large proportion of human population and the im-
mune system is not able to completely eradicate the
viruses.
Moreover, as is the case of CMV, the adaptive immune
responses pay a high price to maintain the virus in the
latent form, since the immune resources involved in
anti-virus defensive mechanisms are elevated. In fact, in
the elderly as many as 50% of cytotoxic CD8 positive T
cells and 30% of the helper CD4 T cells can be positive
Table 1 Effects of persistent virus infections upon the different T cell populations in the peripheral blood of young
and old subjects [modified from Fülöp et al [41]
CMV HBV EBV VZV HSV-1 HHV-6
Expansion +++ + + - - ?
Viral load +/− +/− +/− +/− +/− +/−
Reactivation ? ? ? +/− +/− -
Immune phenotype TEMRA EM EM CM/EM EM TREG
Immunological aging ++++ + ++ - - -
Clinical impact in young Moderate Mild Moderate Mild Mild Moderate/Severe
Clinical impact in elderly Moderate Mild Moderate Severe Mild ?
CM = central memory cells; EM = effector memory cells; TEMRA = terminally differentiated memory cells re-expressing CD45RA.
? = data not available.
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different antigen specificity proportionally and concomi-
tantly decrease.
Decreased protection after vaccination, increased risk
of cardiovascular diseases and type 2 diabetes are the
clinical consequences of the immune system re-shaping
in the elderly. All these conditions are associated with
increased age-associated peripheral inflammation.
Classical and alternatively activated microglia in AD
It has been known for some decades that tissue macro-
phages may be differently activated. These two stages of
metabolic activation have been defined M1 and M2 and
they can be identified by up-regulation of membrane
markers after stimulation by different factors.
M1 macrophages show a pro inflammatory function,
whilst M2 have anti inflammatory activity.
IFN-gamma produced by T helper-1 lymphocytes in-
duces the M1 activation state and these macrophages
produce high levels of TNF-alpha and iNOS [46].
M2 macrophages, also called alternatively activated, do
not release NO, are not cytotoxic, and are activated by T





Figure 1 The change in the percentage of regulatory T cells (Tregs) w13. M2 are considered regulatory macrophages, since
they inhibit the release of several cytokines from other
cells of the immune system [47].
As far as AD neurodegeneration is concerned, there is a
consensus suggesting that the inflammatory milieu associ-
ated with the neuro-inflammation inhibits the microglia
phagocytosis [48]. Moreover, in the PS1M146L/APP751SL
mouse model of AD an age dependent switch of brain
microglia from the alternative to the classical phenotype
was observed [49].
However, other investigations on AD animal models
reported that brain microglia over-expressed markers of
the alternatively activated phenotype [50,48].
Under normal conditions, few activated T cells gain
entry to the brain and are involved in immune surveil-
lance. However, infiltration of a significant number of T
cells occurs in brain disease or after brain injury. The con-
sequences of T cell infiltration may play a neurodestructive
or neuroprotective role in different disease animal models
[48]. A recent paper reviewed this topic concluding
that brain infiltrating T cells regulate microglia activation
by releasing IFN-gamma and, therefore, driving neuro-
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Figure 2 The decline of the immune diversity and plasticity with advancing age in relation to a decrement of immune reserve induced
by antigen load of chronic infections [modified from Fülöp et al. [41].
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neuro-imaging techniques has been reported [51,52].
A defective resolution of inflammatory state has been
recently found in the brain of patients with AD and this
impairment correlated with cognitive function [53].
Moreover, elevated levels of CNS inflammation and CSF
inflammatory markers have been also reported in pre-
clinical stages of AD [54].
In conclusion, brain microglia from AD patients is ac-
tivated and release several cytokines that induce neuro-
inflammation.
Peripheral inflammation and neurodegeneration in AD
As above discussed, inflammatory responses are present
in the brain of patients with AD and activated microglia
cells are a pathological marker of the disease [55].
However, it is important to note that several observa-
tions have also shown that increased peripheral inflamma-
tory responses are detectable in patients with AD [56]. For
instance, increased levels of certain cytokines and acute
phase proteins are well detectable in the blood of AD [57].
Therefore, peripheral inflammatory state is higher in AD
patients than in cognitively healthy elderly [58,56].
It is likely that, as the neurodegenerative processes
progress in the brain, a concomitant increased periph-
eral dis-regulation of immune responses increases.
This notion is supported by several observations. For
instance, a recent report from a study originally designed
to investigate of osteoporotic fractures showed that a
significant change in peripheral inflammatory markers
was present in the oldest-old women and correlated with
cognitive decline [59].
A recent overview of the topic concluded that pub-
lished data were conflicting; however, some cytokinesshowed a steady increase during progression from mild
cognitive decline (MCI) to AD [60].
An association between late life depression, MCI and
AD is well documented and an interesting paper sug-
gested that peripheral inflammation might be the miss-
ing link in these different conditions [61].
Increased serum levels of inflammatory factors have
been reported also in MCI with different genetic back-
ground from China [62].
A recent report by applying sophisticated statistical
analysis to disclose the relationship between immuno-
logical and oxidative stress markers in AD and MCI,
showed that a global immune deficit in MCI and AD
was detectable [63]. In fact, both adaptive and innate im-
munity were peripherally defective. A widespread im-
mune deficit, as suggested in the study, is conceivable to
be a concomitant factor in disease progression both for
inadequate control of local inflammation and for an in-
sufficient supply in repairing factors [63].
We can conclude that peripheral inflammation is in-
deed present in early stage of AD and is higher than that
observed during non pathological aging [60]. Moreover,
an altered inflammatory regulation is also present in
MCI and correlate with the progression to AD [60].
The missing link between central neuro-inflammation and
peripheral inflammatory state: infectious factors
It has been shown from the Rush Alzheimer’s Disease
Center Religious Order that CMV serum levels were as-
sociated with NFT in the autopsy brains [64]. It is of
interest that the percentages of senescent CD4 and CD8
T cells were higher in CMV sero-positive than in sero-
negative subjects and marginally associated with AD
diagnosis. Moreover, Lurain and co-workers reported
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the expression of amyloid beta peptides [64].
Therefore, a more stringent link may bind peripheral
and central inflammatory responses in AD.
This link may consist of chronic infections by microor-
ganisms, such as viruses, that are able to constantly im-
pair immune responses.
Bacterial infection, cognitive decline and dementia
It is important to keep in mind that several pathogens
may show the potential ability to dis-regulate the im-
mune responses.
In fact, virus infections are not the unique challenge
for the aging immune system. Persistent low level bac-
terial infections also play a role in inducing chronic in-
flammation in the elderly. Specifically, oral microbiome
and oral infections have been recently reviewed as po-
tential causes of blood brain barrier (BBB) disruption
and brain inflammation; these pathogens may also infect
the brain via trigeminal and/or olfactory nerves [65].
Chronic inflammation in periodontal disease, for ex-
ample, has been suggested as a potential risk factor in
Alzheimer’s disease [66]. Periodontal disease is a periph-
eral, chronic infection, which elicits a systemic inflam-
matory response [67]. The chronic trickling of Gram
negative, anaerobic periodontal bacteria into the sys-
temic bloodstream result in elevated levels of various
inflammatory mediators in the serum of periodontitis
patients. Some inflammatory mediators associated with
periodontal disease, e.g. C Reactive Protein (CRP), Inter-
leukin 6 (IL 6), Interleukin 1(IL 1β), and TNF-α have
been suggested to increase the risk of cognitive decline
and/or Alzheimer’s disease [66].
In the study of Sparks Stein P et al., both the AD and
MCI subjects demonstrated significant elevations in
antibody to P. intermedia and F. nucleatum at baseline,
prior to diagnosis of the neurological changes. Addition-
ally, the AD subjects expressed significantly elevated
antibody to T. denticola, and P. gingivalis at baseline.
Interestingly, the control group also showed antibody
levels higher than healthy values for four of the seven
bacteria (A. actinomycetemcomitans, C. rectus, T. for-
sythia and P gingivalis) with three of the four at levels
consistent with chronic periodontal disease. Regardless,
the levels of antibodies in the control group were signifi-
cantly lower than the levels of those who converted to
AD at baseline for five of the seven bacteria studied [66].
Whether oral bacteria themselves or endotoxins (e.g.,
LPS) released by them gain access to the brain, the net
result is likely to be microglial activation. Microglial acti-
vation is a well-recognized feature of AD and results in
the increased production of proinflammatory cytokines
such as TNF and IL1β. This could explain why levels of,
for example, TNF in the cerebrospinal fluid of ADpatients reach such high levels, 25-fold that of controls.
Prolonged exposure to high concentrations of TNF
weakens the protective BBB making it more permeable
to ingress of bacteria or endotoxins [65].
Chronic low level inflammation induced by sub clin-
ical infections may therefore play a pivotal role in dir-
ectly or indirectly activate brain immune responses and
neuro-inflammation.
Host genetic makeup, immune responses and dementia
However, it is also relevant how the host responds to
these microorganisms. In fact, the individual genetic
background plays a pivotal role in the maintenance of
the chronic inflammation both in the brain and in the
peripheral tissues.
In this context, as already mentioned, GWA studies in
AD showed that several immune factors were associated
with increased risk of the disease. However, each single
immune gene showed a low odd ratio (OR < 1.7) of asso-
ciation with AD.
The only exception was the allele 4 of the APOE gene
that was confirmed to have a high OR with AD. APOE
gene also appears to be involved in chronic infections
and it is important to note that the APOE gene is a well
known susceptibility factor for several virus infections
[68-70]. Besides, ApoE4 compromises the integrity of the
BBB by activating the cyclophilin A matrix metalloprotein-
ase MMP-9 pathway [71]. This is particularly important if
the penetration of bacteria or LPS into the brain is in-
volved in the initiation or progression of AD [65].
The weak association of immune genes with AD can
be simply explained, as no immune factor is the cause of
the disease. Nevertheless, the concomitant presence of
several genetic factors in the same individual might show
a more sound association and individual infection suscep-
tibility may be affected by the concomitant presence of
alleles resulting in decreased immune efficiency [9,10].
As infections appear to play a role, the link between a
given pathogen and the host susceptibility to its infectiv-
ity might be one missing link in the pathogenesis of cog-
nitive decline progression to clinical AD.
Our recent findings showed that polymorphisms in
genes regulating antiviral responses are differently dis-
tributed in AD and influence a differential positivity to
EBV and HHV-6 genomes in the elderly (data submit-
ted). Moreover, risk alleles were increased in elderly pro-
gressing to AD (data submitted). These observations
reinforce the notion that individual genetic background
plays a role in the progression of cognitive impairment
by influencing the efficiency of immune responses to
persistent parasites.
Different immune genetic makeup will weaken the de-
fensive mechanisms against few pathogens. This immuno-
logical weakness, however, will show relevant effects over
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nisms against other pathogens able to directly infect the
brain or against microorganisms able to produce toxins
which, in turn, impair the BBB and/or kill neurons. All
these mechanisms may have deleterious effects on cogni-
tive performances during aging.
Conclusions
AD is a multi-factorial diseases, which shows different
etiological and pathogenetic factors. Several different
pathogens, both viruses and bacteria, may play a role
in triggering ill controlled inflammatory responses and
directly or indirectly activate neuro-inflammation. An
important role in brain defenses against microorganisms
is played by APP and its peptides. However, in subjects
who will develop AD this protective mechanism appear
to be unsuccessful. Besides, the pathogen induced re-
shaping of adaptive immune responses has deep conse-
quences in the altered regulation of both peripheral and
central immune defensive mechanisms.
Individual susceptibility to different pathogens under
the control of personal genetic background plays a sec-
ondary but not marginal role in the unsuccessful regula-
tion of defensive immune responses and poorly controlled
inflammation. Therefore, the activation of persistent per-
ipheral inflammation has detrimental effect upon the brain
in genetically susceptible individuals.
If this view of the disease will be shared by an increas-
ing number of scientists and experimentally and clinic-
ally verified, several new therapeutic interventions may
open for AD patients. Successful treatment of chronic in-
fections is a challenging but mandatory goal to improve
the quality of life in the elderly.
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